Does albuminuria regression translate into hard renal endpoints?

My laboratory results are from the same laboratory each time, drawn fasting, which I gather matters.

I want to know whether there is evidence behind this or only repetition.

I have checked the obvious registries and monographs without success.

Has anyone verified this independently?

Start by separating the acute haemodynamic effect from the long-term trajectory. They point in opposite directions over the first few weeks and that confuses a lot of readings.

Urinary albumin-to-creatinine ratio falls substantially in this class, often by thirty per cent or more. It is a good surrogate and it is still a surrogate; the reason FLOW mattered is that it measured the thing itself.

Combination with other agents acting on the same haemodynamics changes the picture, and that interaction is a clinical question rather than a pharmacological curiosity.

FLOW is the dedicated kidney-outcome trial in this class and is the appropriate citation for hard renal endpoints rather than a subgroup of a cardiovascular trial.

Nothing here is medical advice, and anyone with existing kidney disease has a genuinely different risk calculus that needs a clinician.

Cite FLOW for hard kidney endpoints, not a cardiovascular trial subgroup.

The honest answer is that the class slows progression in diabetic kidney disease and that no trial has shown it reverses established damage.

Slope-based endpoints — the rate of eGFR decline in millilitres per minute per year — are increasingly used because they need fewer participants than event counts. They are legitimate and they are not events.

Worth being precise here: trials in this area enrol by eGFR band, commonly from twenty-five or thirty upwards. A result from a cohort with eGFR above sixty says little about someone at thirty-five.

Research-use compounds are not approved for human use, and unverified content makes any dose-related renal reasoning unfounded from the start.

Albuminuria is the fast signal and the composite is the answer.

The short version: reduced progression of kidney disease in the population studied, on a hard composite, with an effect size in the same region as the cardiovascular one.

Proteinuria reduction appears early, within months; the divergence in hard endpoints takes years. A trial short enough to see the first is too short to see the second.

Earlier renal findings came as secondary composites within cardiovascular outcome trials and were dominated by the albuminuria component, which is why the dedicated trial mattered.

If gastrointestinal effects are severe enough to affect fluid intake, that is the renal risk worth attending to.

Dehydration secondary to gastrointestinal effects is the practical renal risk in this class, and it is a volume problem rather than a drug-toxicity problem.

FLOW randomised people with type 2 diabetes and chronic kidney disease to semaglutide and reported roughly a twenty-four per cent reduction in the primary kidney composite, which combined kidney failure, sustained large eGFR decline and death from kidney or cardiovascular causes.

A surrogate that moves is encouraging. A surrogate that moves is also how several drug classes in other fields were shown to be useless.

Quote the eGFR entry band with any renal result, or the result does not travel.